Quick Takeaways
- Capital Research Global Investors filed SCHEDULE 13G for Alnylam Pharmaceuticals, Inc. Common Stock (ALNY).
- Disclosed ownership: 5.4%.
- Date of event: 31 Dec 2024.
Capital Research Global Investors - 31 Dec 2024 SCHEDULE 13G Report for Alnylam Pharmaceuticals, Inc. Common Stock (ALNY)
- Filing Manager
- Capital Research Global Investors
- Reporting Manager
- Capital Research Global Investors
- Symbol
- ALNY
- Shares outstanding
- 129,046,537 shares
- Disclosed Ownership
- 6,968,513 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 13 Feb 2025, 14:14:00 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Capital Research Global Investors disclosed 5.4% ownership in Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2025, 14:14.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Capital Research Global Investors | 5.4% | 6,968,513 | 6,959,366 | 0 | Jae Won Chung | Vice President and Senior Counsel II, Capital Research and Management Company |